ASCO GU Conference Coverage
Filter News By:
Featured Articles
(Medscape Medical News) Feb 17, 2020 - For the first time, a clear cell renal cell carcinoma therapy targets a molecular driver of the cancer that was previously believed to be "undruggable," said investigator Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, here at the Genitourinary Cancers Symposium (GUCS)...
Read Article
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data from a phase I trial showed. Overall, 33 of 45 patients responded to pembrolizumab and enfortumab...
Read Article
Latest Articles
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
February 18, 2020
View More
News Commentary
There is no ASCO GU Conference Coverage commentary.

Featured Videos
There are no ASCO GU Conference Coverage videos.
OBR Blog
There are no ASCO GU Conference Coverage blog entries.

OBR Tweets

Jun 02
Thierry Andre, MD, of @SorbonneTest regarding the outcomes of the Keynote-177 study investigating the use of pembro… https://t.co/kDFozF5pa9

Jun 02
Matthew Galsky @MattGalsky, MD, of @IcahnMountSinai shares the design and outcomes of the Javelin Bladder 100 study… https://t.co/yZ3pRhOiOp

Jun 02
Jorge Cortes @GCC_Cortes, MD, of @GACancerCenter on the evolution of CAR-T cell therapies in hematologic malignanci… https://t.co/GM4S2vb9bd

Jun 02
Salvatore Sienna, MD, of @LaStatale on what is next for Enhertu (trastuzumab deruxtecan) in clinical development… https://t.co/M5eqKkvNUH

Jun 02
Howard Hochster @HH_Oncodr, MD, of @RutgersCancer discusses the outcomes of the Keynote-177 study in metastatic CRC… https://t.co/L9tXQmbWIE

Jun 02
Robert Coleman, MD, FACOG, FACS, of @TheUSONetwork discusses the 2 recent FDA approvals for PARP inhibitors in ovar… https://t.co/oertTlYSSQ

Jun 02
Debu Tripathy, MD: The interim analysis of the very large PALLAS trial testing the addition of 2 years of palbocicl… https://t.co/ThMIREhznz

Jun 01
Alan Venook, MD, of @UCSF discusses the Keynote-177 study investigating MSI High/mismatch repair deficient metastat… https://t.co/6Su3IQK7sN

May 31
Yale Cancer Center Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC #ASCO20 https://t.co/SaOmXmhtiU

May 31
Carfilzomib Does Not Improve Outcomes In Newly Diagnosed Myeloma Compared To Bortezomib #ASCO20 https://t.co/fAh0LUHDFh